SHERIDAN, WYOMING – July 29, 2025 – Grupo GEPP, the exclusive bottler for PepsiCo in Mexico, has significantly expanded its returnable PET and glass packaging infrastructure with support from Sidel, reinforcing its long-term strategy to reduce virgin plastic use and align with PepsiCo’s global sustainability roadmap.
SHERIDAN, WYOMING – July 29, 2025 – In a landscape defined by evolving dental materials, Dentsply Sirona’s AH Plus® continues to set the standard in endodontic sealing—celebrating 30 years of clinical trust, scientific validation, and global use across more than 800 million root canal procedures.
Three Decades of Clinical Consistency and Scientific Validation
SHERIDAN, WYOMING – July 29, 2025 – Dentsply Sirona has appointed veteran medtech executive Daniel Scavilla as President and Chief Executive Officer, effective August 1, 2025, in a leadership move designed to accelerate its ongoing transformation, deepen innovation, and unlock new commercial opportunities across the global dental market.
A leadership shift with proven operational impact
SHERIDAN, WYOMING – July 29, 2025 – Dentsply Sirona is doubling down on its commitment to delivering more than just clinical education at DS World Las Vegas 2025 by unveiling a headline entertainment and speaker roster that blends celebrity impact with entrepreneurial insight. Taking place September 25–27 at the MGM Grand, this flagship event will feature Emmy-winning comedian Dana Carvey, Grammy-winning musician Sheryl Crow, and OrangeTheory co-founder Ellen Latham in a format designed to inspire, entertain, and empower the global dental community.
SHERIDAN, WYOMING – July 29, 2025 – Dentsply Sirona is redefining digital chairside workflows with the next evolution of its iconic CEREC system, now seamlessly integrated into the DS Core cloud platform. Celebrating four decades of continuous innovation, the CEREC system combines precision dentistry with real-time digital collaboration—enabling practices to deliver same-day restorations faster, more efficiently, and with greater patient engagement than ever before.
A 40-Year Legacy Meets Modern Cloud Dentistry
SHERIDAN, WYOMING – July 29, 2025 – Bio-Rad Laboratories has named Rajat Mehta as its new Executive Vice President of Global Commercial Operations, signaling a strategic push to accelerate growth across its diagnostics and life sciences business lines. Mehta, whose appointment takes effect August 4, 2025, brings broad cross-sector expertise and a proven track record of commercial execution in the biopharma and scientific instrumentation industries.
New commercial leadership aimed at scaling global market impact
SHERIDAN, WYOMING – July 29, 2025 – In a swift regulatory reversal, the U.S. Food and Drug Administration (FDA) has lifted its recommendation for a voluntary hold on Sarepta Therapeutics’ gene therapy Elevidys for ambulatory Duchenne muscular dystrophy (DMD) patients—restoring immediate commercial viability for the treatment and stabilizing investor confidence after weeks of uncertainty.
FDA Reinstates Ambulatory Access Following Brief Hold
SHERIDAN, WYOMING – July 29, 2025 – Roche has unveiled compelling early-stage data for its next-generation Alzheimer’s therapy, trontinemab, which demonstrated rapid and deep amyloid plaque clearance in patients after just seven months of treatment. The findings, presented at the 2025 Alzheimer’s Association International Conference in Toronto, suggest a potential leap beyond first-generation FDA-approved antibodies and set the stage for a new class of blood-brain barrier-penetrating biologics.
SHERIDAN, WYOMING – July 29, 2025 – Boehringer Ingelheim has entered a strategic collaboration with Re-Vana Therapeutics, aiming to co-develop long-acting injectable therapies for serious eye diseases using Re-Vana’s proprietary sustained-release delivery platform. The multi-target agreement could exceed $1 billion in total value and marks a significant move by Boehringer into the ophthalmology space.
Pioneering extended-release drug delivery for ophthalmology
SHERIDAN, WYOMING – July 29, 2025 – GSK has launched one of the largest licensing collaborations of the year, partnering with China-based Hengrui Pharma in a deal that could reach up to $12 billion. The multi-program alliance aims to accelerate global development of 12 investigational therapies targeting oncology, respiratory diseases, and immunology — marking a major step in GSK’s bid to diversify and deepen its late-stage pipeline.
A strategic cornerstone: HRS-9821 for COPD